O lea ua tu'uina atu e le Komisi a Europa le Fa'atauga Fa'atonu mo le tui Novavax COVID-19

A HOLD Fa'asa'oloto 4 | eTurboNews | eTN

Novavax, Inc., o se kamupani biotechnology tuuto i le atinaʻeina ma le faʻatauina o tui o le isi augatupulaga mo faʻamaʻi pipisi ogaoga, i aso nei ua faʻasalalau mai e le Komisi Europa (EC) ua tuʻuina atu le Novavax conditional marketing authorization (CMA) mo Nuvaxovid™ COVID-19 Vaccine (recombinant, fa'aopoopo) mo tui puipui malosi e puipuia ai le COVID-19 mafua mai le SARS-CoV-2 i tagata ta'ito'atasi 18 tausaga ma matutua atu. O le fa'atagaga e mulimulita'i le Komiti a le European Medicines Agency (EMA) mo Mea Fa'afoma'i mo le Fa'aaogaina e Tagata (CHMP) i aso nei e fa'ataga ai le tui (e ta'ua fo'i o le NVX-CoV2373) ma e fa'aoga i setete uma e 27 Europa Iuni (EU).

Ole manatu ole EMA ma fa'ai'uga a le EC e fa'atatau i le aofa'iga o fa'amaumauga a le falema'i, gaosiga ma fa'ata'ita'iga fa'apitoa na tu'uina atu mo le toe iloiloga. E aofia ai ni fa'ata'ita'iga fa'apitoa e lua o le Vaega 3: PREVENT-19 lea na aofia ai le 30,000 tagata auai i le US ma Mekisiko, o taunu'uga na lomia i le New England Journal of Medicine (NEJM); ma se faʻataʻitaʻiga ma le 15,000 tagata auai i Peretania, o taunuʻuga na faʻasalalau foi i le NEJM. I faʻataʻitaʻiga uma e lua, na faʻaalia ai e le NVX-CoV2373 le maualuga o le aoga ma se faʻamatalaga saogalemu ma le gafatia. Novavax o le a faʻaauau ona aoina ma auʻiliʻili faʻamatalaga moni o le lalolagi, e aofia ai le mataʻituina o le saogalemu ma le iloiloga o fesuiaiga, aʻo tufatufaina atu le tui.

Novavax ma le EC na faʻasalalau se maliega faʻatau muamua (APA) e oʻo atu i le 200 miliona tui ole tui ole Novavax 'COVID-19 ia Aokuso 2021. O tui muamua e faʻamoemoe e taunuʻu i Europa ia Ianuari. Novavax o loʻo galulue faʻatasi ma le EMA ma ana paʻaga e faʻavavevave faʻataʻitaʻiga faʻalotoifale.

O lenei faʻatagaga e faʻaogaina ai le Novavax 'faʻapaʻaga gaosiga ma le Serum Institute of India (SII), o le gaosiga o tui sili ona tele i le lalolagi i le voluma, lea o le a tuʻuina atu muamua tui mo le EU O le a mulimuli ane faʻaopoopo i faʻamaumauga mai nofoaga faʻaopoopo falegaosimea i le Novavax 'faʻasalalauga faʻavaomalo.

Na maua talu ai nei e Novavax ma SII le fa'atagaina o fa'alavelave fa'afuase'i (EUA) i Initonesia ma Filipaina, lea o le a fa'atauina e le SII i lalo o le igoa tau fefa'ataua'iga Covovax™. Na maua foi e kamupani le lisi o faʻaoga faʻafuaseʻi mo Covovax mai le Faalapotopotoga o le Soifua Maloloina a le Lalolagi. O le tui o loʻo iloiloina foʻi e le tele o ofisa faʻatonutonu i le lalolagi atoa, ma o loʻo faʻamoemoe le kamupani e tuʻuina atu lana faʻamaumauga atoa o kemisi, gaosiga ma faʻatonutonu (CMC) i le US Food and Drug Administration (FDA) i le faaiuga o le tausaga.

Fa'atagaina le Fa'aaogaina o Nuvaxovid™ i le Iuni a Europa

Ua tuuina atu e le Komisi a Europa le faatagaga tau maketi mo le Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) mo tui puipui malosi e puipuia ai le COVID-19 e mafua mai i le SARS-CoV-2 i tagata taitoatasi e 18 tausaga ma matutua atu.

Faamatalaga Taua o le Saogalemu

• Nuvaxovid™ e fa'asaina i tagata e maua i le hypersensitivity i le vaila'au malosi po'o so'o se mea fa'aoga.

• O mea na tutupu i anaphylaxis ua lipotia mai ile fa'aogaina ole tui ole COVID-19. O togafitiga faafoma'i talafeagai ma le vaavaaiga e tatau ona avanoa pe a tupu se fa'alavelave anaphylactic

• O fa'alavelave fa'apopoleina, e aofia ai fa'alavelave vasovagal (syncope), fa'amama toto, po'o fa'alavelave fa'apopoleina e ono tupu fa'atasi ma le tui o se tali i le tui o le nila. E taua le faia o puipuiga e aloese ai mai manu'a mai le matapogia

• E tatau ona tolopo le tui i tagata ta'ito'atasi o lo'o maua i se ma'i fiva tu'i tuga po'o fa'ama'i pipisi

Tu'u le Nuvaxovid ma le fa'aeteete i tagata ta'ito'atasi o lo'o maua togafitiga fa'ama'i po'o i latou o lo'o maua i le thrombocytopenia po'o so'o se fa'aletonu o le toto (e pei o le haemophilia) ona e mafai ona tupu le toto po'o le toto'a pe a mae'a le tu'uina atu o le toto i totonu o nei tagata.

• O le aoga o le Nuvaxovid atonu e maualalo i tagata e le atoatoa le puipuiga

• O le umi o le puipuiga e maua e le tui e le o iloa ona o lo'o fa'amauina pea ile fa'ata'ita'iga fa'aauau.

• E le mafai ona puipuia atoatoa tagata ta'ito'atasi se'ia o'o i le 7 aso talu ona mae'a a latou tui lona lua. E pei o tui puipui uma, o le tui ile Nuvaxovid atonu e le puipuia uma tagata e mauaina tui

• O a'afiaga sili ona taatele na matauina i taimi o su'esu'ega fa'afoma'i (vaega masani o le ≥ 1/10), o le ulu o le ulu, faufau po'o le pua'i, myalgia, arthralgia, tiga/tiga i le nofoaga o tui, vaivai ma le vaivai.

OA MEA E AVEA MAI LENEI TUSI:

  • The vaccine is also currently under review by multiple regulatory agencies worldwide, and the company expects to submit its complete chemistry, manufacturing and controls (CMC) data package to the U.
  • Novavax o le a faʻaauau ona aoina ma auʻiliʻili faʻamatalaga moni o le lalolagi, e aofia ai le mataʻituina o le saogalemu ma le iloiloga o fesuiaiga, aʻo tufatufaina atu le tui.
  • Novavax and SII recently received emergency use authorization (EUA) in Indonesia and the Philippines, where it will be commercialized by SII under the trade name Covovax™.

<

E uiga i le tusitala

Linda Hohnholz

Faatonu sili mo eTurboNews fa'avae ile eTN HQ.

lesitala
Faasilasila i
mālō
0 faamatalaga
Manatu Faʻapena
Vaʻai manatu uma
0
E te alofa i ou mafaufauga, faamolemole taʻu mai.x
()
x
Fa'asoa i...